Lineage Cell Therapeutics, Inc. LCTX

What this company does

From our AlloSCOPE platform, we develop, manufacture, and test specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. We are a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. We are developing a portfolio of assets based on this mechanism and our most clinically-advanced program to date is OpRegen (RG6501), an allogeneic retinal pigmented epithelial (RPE) cell replacement therapy currently in Phase 2a development under a worldwide collaboration with F. Hoffman-La Roche Ltd. and Genentech, Inc., a member of the Roche Group (collectively or individually, “Roche” or “Genentech”), for the treatment of geographic atrophy (GA) secondary to dry-AMD. As of December 31, 2025, we had 77 employees, of which 22 were employed by Lineage and 55 were employed by CCN and work in Israel. Our common shares trade on the NYSE American and the Tel Aviv Stock Exchange under the symbol “LCTX.” Lineage was incorporated on November 30, 1990 in the State of California. We call this approach “Replace and Restore”.

Written from the business description in Lineage Cell Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.